Study Summary
This trial is testing whether piperacillin-tazobactam is as good as meropenem for treating blood-stream infections caused by bacteria that are resistant to cephalosporins.
- Beta-Lactam Antibiotic Resistance Bacterial Infection
- Bacterial Blood Infection
- Enterobacteriaceae Infections
Treatment Effectiveness
Effectiveness Progress
Study Objectives
0 Primary · 12 Secondary · Reporting Duration: 30 days and 90 days from randomization
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
meropenem
1 of 2
piperacillin tazobactam
1 of 2
Active Control
Experimental Treatment
1084 Total Participants · 2 Treatment Groups
Primary Treatment: Piperacillin/tazobactam · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Bitterman, Roni, Fidi Koppel, Cristina Mussini, Yuval Geffen, Michal Chowers, Galia Rahav, Lior Nesher, et al.. 2021. “Piperacillin–tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Third-generation Cephalosporin-resistant Enterobacteriaceae: A Study Protocol for a Non-inferiority Open-label Randomised Controlled Trial (peterpen)”. BMJ Open. BMJ. doi:10.1136/bmjopen-2020-040210.
- Roni Oren MD 2019. "PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671967.
Frequently Asked Questions
What is the sample size of this medical experiment?
"Affirmative. As per the information hosted on clinicaltrials.gov, this research is actively recruiting participants; it was launched May 1st 2019 and has been amended for the last time as of July 25th 2022. The study necessitates 1084 patients across a single site." - Anonymous Online Contributor
To what extent can Piperacillin/tazobactam be relied upon for patient safety?
"Having already been approved, the safety of Piperacillin/tazobactam is rated highly and given a score of 3." - Anonymous Online Contributor
Is registration for this clinical trial currently available to patients?
"The information found on clinicaltrials.gov demonstrates that this trial is actively enrolling patients as of now. This programme was initially posted in May 2019 and revised most recently in July 2022." - Anonymous Online Contributor